Method for purifying calsequestrin or domain fusion protein thereof using calcium silicate
The use of calcium silicate for purifying CSQ fusion proteins addresses aggregation and cost issues, ensuring high purity and recovery rates in industrial-scale processes.
Patent Information
- Application Number
- PCT/KR2026/006007
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional methods for purifying calsequestrin (CSQ) fusion proteins face issues such as non-specific aggregation, reduced purity, increased processing time, and high costs due to expensive resins, making them unsuitable for industrial-scale applications.
A method using calcium silicate to selectively bind and purify CSQ fusion proteins through washing and elution processes, eliminating centrifugation and requiring low-cost, inorganic materials, applicable to both batch and chromatography-based processes.
Achieves high-purity and high-recovery rates with simplified processes, reducing costs and enhancing scalability for industrial applications.
Smart Images

Figure KR2026006007_19112026_PF_FP_ABST
Abstract
Description
Method for purifying calciquestrin or its domain fusion protein using calcium silicate
[0001] The present invention relates to a method for purifying calciquestrin or a domain fusion protein thereof using calcium silicate.
[0002] Calsequestrin (CSQ) is a representative calcium-binding protein present in the sarcoplasmic reticulum of muscle cells, containing large amounts of calcium ions (Ca 2+ It possesses the characteristic of being able to store ). Due to this characteristic, the potential for CSQ to be utilized as a fusion partner for the expression and purification of recombinant proteins has been suggested. In particular, since CSQ exhibits the characteristic of aggregating in the presence of calcium, when fused with a target protein, calcium treatment precipitates the fusion protein
[0003] This can be used in purification technology that recovers it by centrifugation.
[0004] However, conventional calcium-based precipitation methods have several limitations. First, CSQ fusion proteins are prone to forming non-specific complex aggregates with host cell proteins or other impurities during the aggregation process caused by calcium. As a result, the precipitate recovered after centrifugation may contain various impurities, leading to a problem of reduced purity in the final purified protein. Furthermore, since this precipitation-based process requires repeated centrifugation steps, it has limitations in that it increases processing time and has low applicability in industrial mass production processes.
[0005] Furthermore, even when calcium-aggregated CSQ fusion proteins are redissolved using chelating agents such as EDTA, they are not completely converted into a monomeric state, and some may remain in a multimer or aggregated state. This phenomenon can reduce purification efficiency and reproducibility by causing the protein to be detected in an unexpected fraction during subsequent purification processes, and in some cases, may also affect protein activity.
[0006]
[0007] Meanwhile, conventional recombinant fusion protein purification technology utilizes various fusion tags such as 6x histidine, MBP, and GST, and in response, specialized chromatographic materials like Ni-NTA, MBP, and GST resins are employed. However, this purification method requires expensive purification resins and involves high processing costs, which leads to increased cost burdens during industrial mass production and repeated use. Furthermore, since most of these purification resins are manufactured from biological or polymer-based materials, the manufacturing process itself is complex and relatively expensive.
[0008] In particular, column-based chromatography processes are preferred over simple bath-type precipitation processes in industrial bioprocesses because they offer advantages in terms of continuous process application and process control. Therefore, there is a need for a new purification platform that can be directly applied to column processes while overcoming the limitations of precipitation-based CSQ systems.
[0009]
[0010] Prior art
[0011] Republic of Korea Published Patent No. 10-2020-0117881 (October 14, 2020)
[0012] The present invention has been devised to solve the problems of the prior art described above, and aims to provide a method for effectively purifying a high-purity fusion protein by selectively adsorbing and separating a protein fused with calsequestrin (CSQ) or its domain using calcium silicate.
[0013]
[0014] Another objective of the present invention is to provide a protein purification method capable of securing high recovery rates and purification efficiency without requiring expensive purification resins, such as existing fusion protein purification materials like Ni-NTA resin, MBP-resin, GST-resin, ion exchange chromatography, or metal affinity chromatography (IMAC).
[0015]
[0016] Another objective of the present invention is to provide a protein purification method that can directly recover a fusion protein selectively bound to calcium silicate through a washing and elution process without a centrifugation-based process for precipitating and recovering the target protein itself.
[0017]
[0018] Another objective of the present invention is to provide a protein purification technology applicable to batch methods as well as chromatography-based processes by enabling the application of calcium silicate not only in a simple mixing method but also in the form of a column packing material.
[0019]
[0020] Another objective of the present invention is to provide a purification platform that is easy to manufacture and capable of mass production by utilizing calcium silicate, a low-cost inorganic material widely used as a construction material, as a protein purification material, and to provide a cost-effective bioprocess technology suitable for industrial scale-up.
[0021]
[0022] Another objective of the present invention is to provide a protein purification system capable of selectively purifying a target protein while minimizing non-specific binding by utilizing the selective affinity between CSQ or its domain and calcium silicate.
[0023]
[0024] However, the problems that this invention seeks to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below.
[0025] To achieve the above objective, the inventors confirmed that when a target protein fused with calsequestrin (CSQ) or a domain or functional fragment maintaining its calcium-binding function is expressed in host cells and calcium silicate is brought into contact with a water-soluble protein extract, the fusion protein selectively binds to the calcium silicate. Furthermore, the present invention was completed by confirming that the bound fusion protein can be effectively recovered with high purity and recovery rate through washing and elution steps.
[0026]
[0027] In particular, the inventors compared the purification efficiency of CSQ fusion proteins using calcium silicate, magnesium silicate, zinc silicate, and hydroxyapatite, and confirmed that the best purification efficiency and recovery rate were obtained when calcium silicate was used. In particular, as confirmed in Examples 1 to 4, when calcium silicate was used, a high recovery rate of over 98% and excellent purification efficiency were secured, which was a significantly superior result compared to the existing CaCl₂-based precipitation method.
[0028]
[0029] Furthermore, the inventors confirmed that CSQ or CSQ domain I-II itself has a high affinity for calcium silicate. In Example 6, it was confirmed that CSQ and CSQ domain I-II proteins, which are not fused with the target protein, also selectively bind to calcium silicate and can be effectively purified. On the other hand, in Example 7, it was confirmed that Protein G proteins, which are not fused with CSQ or CSQ domain I-II, do not substantially bind to calcium silicate. These results support the purification principle of the present invention, which is based on the specific affinity between CSQ or its domains and calcium silicate.
[0030]
[0031] In addition, it was confirmed that by controlling the particle size of the calcium silicate used in the present invention to a range of about 100 to 3000 μm, the fusion protein bound to the calcium silicate can be easily separated by gravity sedimentation or simple filtration. Accordingly, protein recovery is possible without a centrifugation process to precipitate the target protein itself as in the conventional method, and the process is significantly simplified.
[0032]
[0033] Furthermore, since calcium silicate can be applied in the form of a column packing material, it can be effectively utilized not only in batch methods but also in column-based chromatography methods. In fact, in Example 5, after packing calcium silicate into an open column and purifying the CSQ fusion protein, it was confirmed that the fusion protein could be recovered with high purity and recovery rate even by the column method.
[0034]
[0035] Accordingly, the present invention provides a low-cost, high-efficiency inorganic material-based protein purification platform applicable to recombinant proteins fused with CSQ or a domain thereof.
[0036] According to the method for purifying calsequestrin (CSQ) or a domain fusion protein fused with the same using calcium silicate according to the present invention, a target protein fused with CSQ or its domain can be effectively separated and purified with high selectivity and recovery rate.
[0037]
[0038] Furthermore, since the present invention allows for the direct recovery of the fusion protein bound to calcium silicate through washing and elution processes without precipitating the target protein itself, a centrifugation-based precipitation process is eliminated, thereby simplifying the process. Accordingly, it can be easily applied to industrial scale-up processes.
[0039]
[0040] In addition, by controlling the particle size of calcium silicate, protein separation is possible using only gravity sedimentation or filtration methods, thereby improving process efficiency and processing convenience.
[0041]
[0042] Furthermore, calcium silicate can be utilized as a column packing material, making it applicable not only to batch processes but also to chromatography-based continuous processes, and providing higher process flexibility compared to existing protein purification platforms.
[0043]
[0044] In addition, the present invention enables selective purification of fusion proteins while minimizing non-specific binding by utilizing the affinity between CSQ or its domain and calcium silicate.
[0045]
[0046] In addition, calcium silicate is a low-cost inorganic material widely used as a construction material, and since it is easy to manufacture and can be mass-produced, purification costs can be significantly reduced compared to existing fusion protein purification affinity resins or metal affinity resins (IMAC resin).
[0047]
[0048] Accordingly, the present invention provides an excellent protein purification technology that simultaneously offers high purification efficiency, process simplicity, low cost, and industrial scalability.
[0049]
[0050] Meanwhile, the above-mentioned effects are exemplary and do not limit the scope of the present invention.
[0051] Figure 1 is a diagram showing the results of comparing separation and purification efficiency through SDS-PAGE and densitometry analysis after treating various inorganic materials with a ZZ-CSQ (ZZ, two Z domains of protein A) fusion protein.
[0052] Figure 2 is a diagram showing the results of comparing separation and purification efficiencies through SDS-PAGE and densitometry analysis after treating various inorganic materials with CSQ-Protein G fusion protein.
[0053] Figure 3 is a diagram showing the results of comparing separation and purification efficiency through SDS-PAGE and densitometry analysis after treating various inorganic materials with a protein fused with GFP using CSQ domains I-II as fusion partners.
[0054] Figure 4 is a diagram showing the results of comparing separation and purification efficiencies through SDS-PAGE and densitometry analysis after treating various inorganic materials with a protein in which CSQ domains I-II were fused to Protein G.
[0055] Figure 5 is a diagram showing the results of separating and purifying CSQ-GFP fusion proteins by chromatography using calcium silicate in the form of an open column.
[0056] Figure 6 is a diagram showing the results of applying the same method as in Figure 5 to a ZZ-CSQ fusion protein.
[0057] Figure 7 is a diagram showing the results of separation and purification of non-fusion Protein G protein using calcium silicate.
[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which this disclosure pertains. Any method, material, composition, reagent, or cell similar or equivalent to that described herein may be used to carry out or test the subject matter of this disclosure, but preferred methods and materials are described. All publications and references, including but not limited to patents and patent applications cited herein, are incorporated herein by reference in their entirety as indicated, so that each individual publication or reference is incorporated herein by reference in its entirety as specifically and individually presented. Any patent application for which this application claims priority is also incorporated herein by reference in its entirety in the manner described above with respect to publications and references.
[0059] As used herein, the term "amino acid" refers to both natural and non-natural amino acids, as well as amino acid analogs and mimics. Natural amino acids include 20(L)-amino acids used during protein biosynthesis, as well as others such as, for example, 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, homocysteine, citrulline, and ornithine. Non-natural amino acids include, for example, (D)-amino acids, norleucine, norvaline, p-fluorophenylalanine, ethionine, etc., which are known to those skilled in the art. Amino acid analogs include modified forms of natural and non-natural amino acids. Such modifications may include, for example, the substitution or replacement of chemical groups and moiety on the amino acid, or the derivatization of the amino acid. Amino acid mimics include organic structures that exhibit functionally similar properties, such as the charge and charge spacing characteristics of the reference amino acid, for example. For example, an organic structure mimicking arginine (Arg or R) will have a positively charged moiety located in a similar molecular space and having the same degree of mobility as the e-amino group of the side chain of the natural Arg amino acid. The mimic also includes a structure forced to maintain optimal spacing and charge interactions of the amino acid or amino acid functional group. A person skilled in the art may know or determine the structures constituting functionally equivalent amino acid analogs and amino acid mimics.
[0060] As used herein, the terms “polypeptide,” “protein,” and “peptide” are used interchangeably and refer to a polymer of amino acids not limited to any specific length. The term “polypeptide” or “protein” refers to a chain of one or more amino acids, wherein each chain comprises amino acids covalently linked by peptide bonds, and said polypeptide or protein may comprise a plurality of chains non-covalently and / or covalently linked together by peptide bonds having a sequence of a natural protein, i.e., a natural and specifically non-recombinant cell, or a protein produced by a genetically engineered or recombinant cell, and may comprise a molecule having an amino acid sequence of a natural protein, or a molecule having a deletion, addition, and / or substitution thereof from one or more amino acids of the natural sequence. In certain embodiments, the polypeptide is a “recombinant” polypeptide produced by a recombinant cell comprising one or more recombinant DNA molecules, which typically consists of a heterogeneous polynucleotide sequence or a combination of polynucleotide sequences that would not otherwise be found in the cell.
[0061] As used herein, the terms “polynucleotide” and “nucleic acid” include mRNA, RNA, cRNA, cDNA, and DNA. The terms refer to polymeric forms of nucleotides having a length of at least 10 bases, typically ribonucleotides or deoxynucleotides or modified forms of either type of nucleotide. The terms include DNA in single and double-stranded forms. The terms “isolated DNA,” “isolated polynucleotide,” and “isolated nucleic acid” refer to molecules isolated without the whole genomic DNA of a particular species. Thus, an isolated DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences but is substantially isolated or purified from the whole genomic DNA of the species from which the DNA segment is obtained. Additionally, non-coding polynucleotides that do not encode polypeptides (e.g., primers, probes, oligonucleotides) are included. Additionally, recombinant vectors are included, for example, expression vectors, viral vectors, plasmids, cosmids, phages, viruses, etc.
[0062] As used in this specification, the term “fusion” refers to a form in which two or more proteins are artificially linked, and in the present invention, it refers to a protein in which calciquestrin is linked to a bioactive substance. Such a fusion protein may be obtained by chemically conjugating or by expressing and purifying it using a genetic recombination method. There are no specific restrictions on the linkage order of calciquestrin and the bioactive substance in the fusion protein, and it may include both “terminus - calciquestrin - target protein - C-terminus” and “terminus - target protein - calciquestrin - C-terminus” forms.
[0063]
[0064] The present invention relates to a method for effectively separating and purifying a target protein fused with calsequestrin (CSQ) or a domain or functional fragment maintaining its calcium-binding function using calcium silicate.
[0065] Conventional protein purification technologies primarily utilize antibody-based affinity resins, ion exchange resins, or salt precipitation processes. However, these methods have limitations, such as requiring expensive purification resins, complex processes, and centrifugation processes to precipitate and recover the target protein itself. Additionally, there was a problem in that protein activity could be reduced or the recovery rate decreased due to non-specific precipitation.
[0066] In contrast, the inventors conducted research based on the observation that CSQ or its domains can exhibit selective affinity for the surface of calcium silicate, an inorganic material. As a result, they confirmed that CSQ fusion proteins can be selectively separated and purified using calcium silicate without the need for a separate high-value affinity resin. Furthermore, they confirmed that the calcium silicate can be applied not only in a simple mixing method but also in the form of a column packing material, thereby expanding into a chromatographic purification platform that replaces precipitation-based processes.
[0067] In particular, the purification method according to the present invention is distinguished from conventional calcium precipitation methods in that it recovers the target protein in the form of elution from CSQ or calcium silicate to which its domain is bound, rather than by precipitating and recovering the target protein itself. That is, the present invention is characterized by having structural advantages that allow for the application of column-based processes without requiring a centrifugation process for the precipitation and recovery of the target protein, while ensuring high purity and recovery rates.
[0068]
[0069] 1. Purification method of fusion proteins
[0070] The present invention aims to provide a method for purifying a fusion protein comprising the step of contacting calcium silicate with an aqueous solution containing a target protein fused with calciquestrin or a domain thereof.
[0071] In the method for purifying a fusion protein according to the present invention, the aqueous solution may be a cell lysate containing a fusion protein expressed in a host cell, a water-soluble protein extract, a culture supernatant, or a partially purified protein solution, but is not limited thereto. According to one embodiment, the host cell may be Escherichia coli (E. coli), Bacillus subtilis, yeast, insect cell, CHO cell, HEK293 cell, COS-7 cell, or plant cell, and preferably may be Escherichia coli (E. coli).
[0072] In the purification method according to the present invention, the average diameter of the calcium silicate may be about 100 to 3000 μm. The calcium silicate may be in the form of a powder, bead, granule, porous particle, or column packing material, and may be appropriately selected depending on the type of target protein or the purification method.
[0073] In the purification method according to the present invention, the purification method is:
[0074] (a) a step of binding a target protein fused with CSQ or a domain thereof to calcium silicate;
[0075] (b) a step of removing non-specifically bound proteins using a washing buffer; and
[0076] (c) may include a step of eluting and recovering the combined fusion protein.
[0077] The washing step described above may be performed using Tris-Cl buffer, phosphate buffer saline (PBS), borate buffer, or any buffer solution known in the art. According to one embodiment, washing may be performed using 20 mM Tris-Cl (pH 7.0) buffer.
[0078] The above elution step can be performed using an alkaline buffer with a pH of 9 to 11. According to one embodiment, a borate buffer with a pH of 10 can be used.
[0079] The purification method of a fusion protein according to the present invention is characterized by not necessarily including a process of recovering the precipitated protein through a centrifugation process, unlike the conventional calcium salt-based precipitation method which recovers the target protein itself by precipitating it. That is, in the present invention, since CSQ or its domain fusion protein selectively bound to calcium silicate can be directly recovered in a water-soluble state through washing and elution processes, a separate step of precipitation generation and recovery is not required. In this respect, the present invention is clearly distinguished from the conventional method of directly precipitating the target protein using CaCl₂ and then recovering it through centrifugation. In fact, as a result of performing the CaCl₂-based precipitation method in the comparative examples of Examples 1 to 4, it was confirmed that the purification method using calcium silicate exhibited significantly higher purification efficiency and recovery rate compared to this.
[0080] In the purification method of a fusion protein according to the present invention, the calcium silicate is formed in the form of a column packing material and can be applied by a chromatographic method. Specifically, after packing the calcium silicate into a column, when an aqueous solution containing the fusion protein is passed through the column, the protein fused with CSQ or its domain selectively binds to the calcium silicate, and the target protein can be recovered through subsequent washing and elution steps. Accordingly, the present invention is applicable not only to batch methods but also to column-based continuous purification processes, thereby facilitating process automation and expansion to continuous processing, and improving processing efficiency and process reproducibility in mass production environments.
[0081] According to one embodiment, purification using calcium silicate was performed on various fusion proteins, and very excellent purification efficiency was confirmed. For example, in the case of the ZZ-CSQ fusion protein of Example 1, the Protein G-CSQ fusion protein of Example 2, the CSQ domain I-II-GFP fusion protein of Example 3, and the CSQ domain I-II-Protein G fusion protein of Example 4, high purity and recovery rates were observed when calcium silicate was used, and in particular, a high recovery rate of about 98% or more was confirmed in Examples 1 and 3. On the other hand, relatively low purification efficiency was observed when magnesium silicate, zinc silicate, and hydroxyapatite were used, and in the case of the protein precipitation method using CaCl₂, a purification efficiency of less than half that of calcium silicate was observed (Examples 1 to 4). These results suggest that calcium silicate has significantly superior selective binding characteristics to CSQ fusion proteins compared to other inorganic materials.
[0082] In addition, it was confirmed that CSQ or CSQ domain I-II itself has a high affinity for calcium silicate. In Example 6, calcium silicate purification was performed on the CSQ and CSQ domain I-II proteins themselves, which were not fused with the target protein. As a result, high-purity proteins were recovered through simple washing and elution processes alone, showing recovery rates of approximately 85% and 70%, respectively. On the other hand, in Example 7, purification was performed under the same conditions on Protein G proteins that were not fused with CSQ or CSQ domain I-II. As a result, Protein G proteins did not substantially bind to calcium silicate and were mostly detected in the unbound fraction. This supports the fact that the purification principle of the present invention is based on the affinity between CSQ or its domains and calcium silicate, rather than the target protein itself.
[0083]
[0084] In the method for purifying a fusion protein according to the present invention, the calciquestrin may consist of the amino acid sequence of SEQ ID NO. 1.
[0085] In the method for purifying a fusion protein according to the present invention, the calciquestrin domain may be composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 2 to 7.
[0086] In the method for purifying a fusion protein according to the present invention, the target protein may be one or more selected from the group consisting of high molecular weight proteins, peptides, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes, antibodies, and synthetic preparations. For example, the above bioactive substances are Interleukin-2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase (HRP), cytokines, α-interferon, β-interferon, γ-interferon, colony-stimulating factor (GM-CSF), human fibronectin extra domain B (EBD), fibroblast growth factor (FGF), nerve growth factor (NGF), insulin-like growth factor (IGF), transforming growth factor (trans-forming growth factor-α and -β, TGF-α, -β), brain-derived neutrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), Hepatocyte growth factor (HGF), Exendin, somatostatin, LHRH (luteinizing hormone-releasing hormone), adrenocorticotropic hormone, growth hormone-releasing hormone, oxytocin, thymosin alpha-1, corticotropin-releasing factor,Calcitonin, bivalirudin, vasopressin, phospholipase-activated protein (PLAP), insulin, tumor necrosis factor (TNF), vesicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, chromogenic hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide (CGPR), enkephalin, somatomedin, erythropoietin, hypothalamic-secreted factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone releasing peptide (GHPR), thymic humoral factor (THF), asparaginase, arginase, arginine deaminase, adenosine deaminase, peroxide dismutase, Endotoxinase, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucodase, galactosidase, glucocerebrosidase, glucouronidase, keratinocyte growth factor (KGF), exenatide, doxorubicin, anti-vascular endothelial growth factor (Anti-VEGF scFv), SARS-Cov2 RBD (receptor binding domain), epidermal growth factor (EGF), fibroblast growth factor-2, bone morphogenetic protein (BMP2), transforming growth factor, vascular endothelial growth factor (VEGF),It may be one or more selected from the group consisting of glucagon-like peptide-1 (GLP-1), TEV protease, HRP enzyme, human growth hormone (hGH), and hematopoietic growth factor (G-CSF), but is not limited thereto. According to one exemplary embodiment, GFP, hGH, Protein-G, Protein-A, Ag85b, M201, and M301 were used as the target proteins.
[0087] In the method for purifying a fusion protein according to the present invention, the fusion protein may be prepared using a recombinant expression vector. The expression vector may include a linker sequence between a CSQ or its domain and a target protein, and the linker sequence may be one or more of GGGGS, GSGSGS, or (GGGGS)n (n=1 to 10) repeat sequences. Additionally, the vector may further include a cleavage site to facilitate the recovery of the target protein, and the cleavage site may be one or more of a thrombin recognition sequence (LVPRGS), an enterokinase recognition sequence (DDDDK), a TEV protease recognition sequence (ENLYFQG), or a factor Xa recognition sequence (IEGR).
[0088]
[0089] 2. Adsorbent
[0090] The present invention aims to provide a calcium silicate adsorbent capable of selectively binding to a protein fused with calsequestrin (CSQ) or a domain thereof.
[0091] The calcium silicate adsorbent can selectively adsorb CSQ fusion proteins even within complex biological samples based on the high affinity between CSQ or its domains and calcium silicate. According to one embodiment, the calcium silicate adsorbent may be prepared in the form of a powder, bead, granule, porous particle, membrane, or column packing.
[0092] The calcium silicate adsorbent described above can be provided in the form of a column packing material and used for protein purification by chromatography. For example, after packing calcium silicate into an open column, an aqueous solution containing CSQ or a protein fused with its domain can be passed through the column, and the target protein can be effectively separated and purified by performing washing and elution steps. In fact, in Example 5, when CSQ-GFP and ZZ-CSQ fusion proteins were purified using calcium silicate as a column packing material, it was confirmed that the proteins were recovered with high purity and recovery rate. These results suggest that calcium silicate can be effectively applied to column-based chromatography purification platforms, going beyond being a simple precipitation adsorbent.
[0093]
[0094] 3. Kit
[0095] The present invention aims to provide a protein purification kit for purifying a protein fused with calciquestrin or a domain thereof.
[0096] The above protein purification kit is:
[0097] (a) calcium silicate; and
[0098] (b) Wash buffer and elution buffer for the purification of proteins fused with calciquestrin or its domain
[0099] It may include.
[0100] The washing buffer may be Tris-Cl buffer, phosphate buffered saline (PBS), borate buffer, or a similar buffer solution, and preferably may be 20 mM Tris-Cl (pH 7.0) buffer.
[0101] The above elution buffer can be performed using an alkaline buffer with a pH of 9 to 11. According to one embodiment, a borate buffer with a pH of 10 can be used.
[0102] The above protein purification kit may further include instructions, a column, a filtration device, reaction tubes, or additional buffer solution as needed.
[0103] Various embodiments are presented below to aid in understanding the invention. The following embodiments are provided merely to facilitate a better understanding of the invention and do not limit the scope of protection of the invention to the following embodiments.
[0104]
[0105] <Example>
[0106] Example 1. Isolation and Purification of ZZ-CSQ Fusion Protein
[0107] The ZZ domain includes the antibody binding domain of Protein A, and in this example, a ZZ-CSQ fusion protein in which calsequestrin (CSQ, SEQ No. 1) is fused to the C-terminus of the ZZ domain was expressed using Escherichia coli (E. coli). After expression, the cells were lysed and a water-soluble protein extract was obtained by centrifugation (lane 1).
[0108] Calcium silicate, magnesium silicate, zinc silicate, and hydroxyapatite (final concentration 25 mg / mL) were each mixed in equal volumes (200 μL) to 200 μL of the obtained water-soluble protein. The mixture was reacted at room temperature for 5 minutes, then centrifuged at 4000 rpm for 10 seconds to remove the supernatant. Next, the mixture was washed once with 1 mL of 20 mM Tris-Cl (pH 7.0) buffer and centrifuged again under the same conditions to remove the supernatant.
[0109] To recover the adsorbed fusion protein, 200 μL of 0.1–0.5 M borate buffer (pH 10) was added and reacted for 5 minutes, and the supernatant was recovered after spin-down. As a comparative example, 50 mM CaCl₂ was added to a water-soluble protein extract to precipitate the protein, then 50 mM EDTA (20 mM Tris-Cl (pH 7.0)) solution was added to resuspend the protein, and the protein was recovered after spin-down.
[0110] As a result of analyzing the recovered protein samples by SDS-PAGE (Fig. 1), the use of calcium silicate showed a separation and purification efficiency of over 98%, while the use of magnesium silicate, zinc silicate, and hydroxyapatite showed relatively lower purification efficiencies. In addition, the precipitation method using CaCl₂ showed a purification efficiency of less than half compared to the use of calcium silicate. Meanwhile, densitometry analysis was performed on each sample using GelAnalyzer software, and the results are shown in the bottom graph of Fig. 1.
[0111]
[0112] Example 2. Isolation and Purification of Protein G-CSQ Fusion Protein
[0113] Protein G-CSQ fusion protein, in which CSQ (Sequence No. 1) is fused to the N-terminus of Protein G, was expressed in E. coli, and then a water-soluble protein extract was obtained through cell lysis and centrifugation.
[0114] The isolation and purification of the fusion protein was performed under the same conditions as in Example 1. Specifically, calcium silicate was added to the water-soluble protein extract and reacted at room temperature, followed by spin-down and washing steps, after which the protein was recovered using Borate Buffer (pH 10). As a comparative example, a precipitation method using magnesium silicate, zinc silicate, hydroxyapatite, and CaCl₂ was performed under the same conditions.
[0115] As a result of analyzing the recovered protein samples by SDS-PAGE (Fig. 2), the highest protein separation recovery rate was observed when calcium silicate was used, while the precipitation method using CaCl₂ showed a relatively low recovery rate (lane 6).
[0116]
[0117] Example 3. Isolation and Purification of CSQ Domain I-II Fusion GFP Protein
[0118] A CSQ-GFP fusion protein was prepared in E. coli by fusing domains I and II of the CSQ protein (SEQ No. 5) to the N-terminus of GFP (green fluorescent protein). After expression, the cells were lysed and centrifuged to obtain a water-soluble protein extract (lane 1). The isolation and purification of the fusion protein were performed in the same manner as in Example 1.
[0119] As a result of analyzing the protein samples recovered after purification by SDS-PAGE (Fig. 3), a recovery rate of over 98% was observed when calcium silicate was used. On the other hand, when magnesium silicate, zinc silicate, hydroxyapatite, and the CaCl₂ precipitation method were used, a recovery rate of less than half was observed in all cases.
[0120]
[0121] Example 4. Isolation and Purification of CSQ Domain I-II - Protein G Fusion Protein
[0122] A CSQ-Protein G fusion protein, in which domains I and II (SEQ No. 5) of the CSQ protein were fused to the N-terminus of Protein G, was expressed in E. coli. After expression, the cells were lysed and centrifuged to obtain a water-soluble protein extract.
[0123] The isolation and purification of the fusion protein was performed under the same conditions as in Example 1. Specifically, calcium silicate was added to the water-soluble protein extract and reacted at room temperature, followed by spin-down and washing steps, after which the protein was recovered using Borate buffer (pH 10). As a control group, precipitation methods using magnesium silicate, zinc silicate, hydroxyapatite, and CaCl₂ were performed under the same conditions.
[0124] As a result of analyzing the recovered protein samples by SDS-PAGE (Fig. 4), the highest protein recovery rate was observed when calcium silicate was used, and it showed superior separation and purification efficiency compared to the precipitation method using magnesium silicate, zinc silicate, hydroxyapatite, and CaCl₂.
[0125] The above results demonstrate that calcium silicate can be utilized as an effective means for protein separation and purification, even for fusion proteins containing only domains I and II of CSQ.
[0126]
[0127] Example 5. Column separation and purification using calcium silicate
[0128] After packing 0.5 g of calcium silicate into an open column, 2 mL (lane 1) of a soluble protein sample of the CSQ (SEQ No. 1)-GFP fusion protein expressed in E. coli was loaded onto the column. Subsequently, the flow-through was recovered (lane 2), and the column was washed with 20 mL of 20 mM Tris-Cl (pH 7.0) buffer. Then, the fusion protein was eluted using 2 mL of pH 10.0 borate buffer (lane 3). Finally, the protein remaining on the calcium silicate was recovered and analyzed (lane 4).
[0129] As a result of analyzing each recovered fraction by SDS-PAGE (top of Fig. 5), it was confirmed that CSQ-GFP fusion proteins with high purity and recovery rates could be isolated and purified using a calcium silicate column method. Column isolation and purification were also performed on ZZ-CSQ (Sequence No. 1) fusion proteins using the same method. Specifically, a water-soluble protein sample of the ZZ-CSQ fusion protein expressed in E. coli was loaded onto a calcium silicate-packed column, and after washing and elution, each fraction was analyzed by SDS-PAGE.
[0130] As a result (bottom of Fig. 5), it was confirmed that the ZZ-CSQ fusion protein was also effectively purified with high purity and recovery rate using the column method.
[0131] From the results of the two SDS-PAGE analyses above, it was confirmed that there was no significant difference in purification performance regardless of whether CSQ was fused to the N-terminus or the C-terminus of the target protein.
[0132]
[0133] Example 6. Isolation and purification of CSQ and CSQ domain I and II proteins using calcium silicate
[0134] In this embodiment, by performing separation and purification using calcium silicate on the CSQ protein and the CSQ domain I and II proteins themselves without fusion with the target protein, we intended to confirm that the purification of the fusion protein is due to the affinity between the CSQ or CSQ domain I and II and the calcium silicate.
[0135] Specifically, separation and purification were performed on a water-soluble protein sample containing CSQ protein and CSQ domain I-II proteins expressed in E. coli using calcium silicate under the same conditions as in Example 1.
[0136] As a result (Fig. 6), it was confirmed that both the CSQ protein and the CSQ domain I-II proteins were effectively purified using calcium silicate. As confirmed in lanes 3 and 4 of the SDS-PAGE analysis results (Fig. 6), high-purity proteins could be obtained with only simple adsorption, washing, and elution processes.
[0137] In addition, the protein recovery rate was approximately 85% for CSQ protein and approximately 70% for CSQ domain I-II protein.
[0138] The above results suggest that CSQ and CSQ domains I-II themselves have a high affinity for calcium silicate, and that this characteristic is a major factor enabling the effective separation and purification of fusion proteins.
[0139]
[0140] Example 7. Comparison of Isolation and Purification of Non-Fusion Proteins Using Calcium Silicate
[0141] In this embodiment, by performing separation and purification using calcium silicate on a protein in which CSQ or CSQ domains I-II are not fused, we intended to confirm that the binding characteristics with calcium silicate identified in the preceding embodiments are attributed to CSQ or CSQ domains I-II.
[0142] Specifically, a Protein G protein in which CSQ or CSQ domains I-II are not fused was expressed in E. coli, and a water-soluble protein extract was obtained. Subsequently, separation and purification using calcium silicate were performed under the same conditions as in Example 1.
[0143] As a result of analyzing each fraction by SDS-PAGE after purification (Fig. 7), it was confirmed that Protein G protein did not substantially bind to calcium silicate. In particular, most of the Protein G protein was detected in the unbound fraction of lane 2, which means that Protein G protein was recovered as is without being adsorbed to calcium silicate.
[0144] The above results support the fact that the proteins fused with CSQ or CSQ domains I-II in the preceding examples could be effectively bound to and purified by calcium silicate, not due to the characteristics of the target protein itself, but due to CSQ or CSQ domains I-II.
[0145]
[0146] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
[0147]
[0148] Research Project Information:
[0149] [Project ID] 2420027467
[0150] [Ministry Name] Ministry of SMEs and Startups
[0151] [Specialized Research Management Agency] Korea Technology Information Promotion Agency for SMEs
[0152] [Research Project Name] Startup Growth Technology Development Project
[0153] [Research Project Title] Development of EasyTag-based Production Process for Non-expressing Proteins Service
[0154] [Organizing Organization] ToolBio
[0155] [Sequence No. 1] Full CSQ amino acid sequence
[0156] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAEEEFHPYIPFFATFD SKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDD
[0157] [Sequence No. 2] CSQ domain 1 amino acid sequence
[0158] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLE
[0159] [Sequence No. 3] CSQ domain 2 amino acid sequence
[0160] DPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRS
[0161] [Sequence No. 4] CSQ domain 3 amino acid sequence
[0162] TLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDDD
[0163] [Sequence No. 5] CSQ domain 1 and 2 amino acid sequences
[0164] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADT IVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAEEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRS
[0165] [Sequence No. 6] CSQ domain 1 and 3 amino acid sequences
[0166] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLETLRKL KPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDDD
[0167] [Sequence No. 7] CSQ domain 2 and 3 amino acid sequences
[0168] DPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDD
Claims
1. A method for purifying a fusion protein, comprising the step of contacting calcium silicate with an aqueous solution containing a target protein fused with calsequestrin (CSQ) or a domain thereof.
2. In Paragraph 1, A method characterized in that the calcium silicate selectively binds to a target protein fused with the calciquestrin or a domain thereof.
3. In Paragraph 1 or 2, The above purification method is, (a) a step of binding the target protein fused with the calciquestrin or its domain to calcium silicate; (b) a step of performing a washing step; and (c) A method characterized by including the step of eluting and recovering a fusion protein bound to the calcium silicate.
4. In Paragraph 3, A method characterized in that the above elution is performed using an alkaline buffer with a pH of 9 to 11.
5. In Paragraph 4, A method characterized in that the above alkaline buffer is a borate buffer with a pH of 10.
6. In Paragraph 4, A method characterized in that the alkaline buffer is a borate buffer with a pH of 8 to 11.
7. In Paragraph 1, The above purification method is characterized by being performed without a centrifugation process to precipitate and recover the target protein itself.
8. In Paragraph 1, A method characterized in that the average diameter of the calcium silicate is 100 to 3000 μm.
9. In Paragraph 1, A method characterized in that the calcium silicate is in the form of powder, beads, granules, porous particles, or column filler.
10. In Paragraph 1, A method characterized by packing the calcium silicate in the form of a column and separating the fusion protein by passing the aqueous solution through the column.
11. In Paragraph 1, A method characterized in that the above aqueous solution is a cell lysate containing calciquestrin expressed from a host cell or a protein fused with a domain thereof, a water-soluble protein extract, a culture supernatant, or a partially purified protein solution.
12. In Paragraph 1, A method characterized in that the host cell is Escherichia coli, Bacillus subtilis, yeast, insect cell, CHO cell, HEK293 cell, COS-7 cell, or plant cell.
13. In Paragraph 1, A method characterized in that the above calciquestrin consists of the amino acid sequence of SEQ ID NO.
1.
14. In Paragraph 1, A method characterized in that the domain of the calciquestrin comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 2 to 7.
15. In Paragraph 1, A method characterized in that the above-mentioned fusion protein is prepared using a recombinant expression vector.
16. In Paragraph 15, A method characterized in that the above expression vector includes a linker sequence between calsequestrin or its domain and a target protein.
17. In Paragraph 16, A method characterized in that the above linker sequence is one or more of GGGGS, GSGSGS, or (GGGGS)n (n=1~10) repeat sequences.
18. In Paragraph 15, A method characterized in that the above expression vector further comprises a cleavage site between calsequestrin or its domain and a target protein.
19. In Paragraph 18, A method characterized in that the above-mentioned cleavage site is one or more of a thrombin recognition sequence (LVPRGS), an enterokinase recognition sequence (DDDDK), a TEV protease recognition sequence (ENLYFQG), or a factor Xa recognition sequence (IEGR).
20. A calcium silicate adsorbent used for selectively binding a protein fused with calsequestrin (CSQ) or a domain thereof.
21. In Paragraph 20, The above calcium silicate adsorbent is an adsorbent characterized by being in the form of a column filler. 22.(a) calcium silicate; and (b) Wash buffer and elution buffer for the purification of proteins fused with calciquestrin or its domain Protein purification kit containing
